MS and Demyelinating Disorders

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

Here's some of what is coming soon to NeurologyLive® this week.

As part of our monthly clinician spotlight, NeurologyLive® highlighted rare disease medicine expert Paula Barreras, MD, a physician neurologist and neuroimmunologist at Cedars Sinai Medical Center.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders.

In recent news, Health Canada approved inebilizumab for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive, using results from the N-MOmentum trial as the basis for the approval.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 26, 2024.

A recent analysis revealed a reduction in regulatory lymphocyte subsets in patients with NMOSD before tocilizumab therapy, with subsequent restoration to normal levels after 1 year treatment.

A recent study showed a more than 75% reduction in migraine frequency in participants with comorbid multiple sclerosis when treated with calcitonin gene-related peptide monoclonal antibodies.

The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic provided perspective on recently published research showing geographic disparities to neurologists and multiple sclerosis centers. [WATCH TIME: 3 minutes]

In a recent study, investigators observed a substantial up-regulation of long noncoding RNAs among patients with neuromyelitis optica spectrum disorder in comparison with heathy individuals.

Ahmed Obeidat, MD, PhD, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.

Tanuja Chitnis, MD, discusses the use of ultra-sensitive assays to determine protein levels in the blood, which may aid in the diagnosis of MS.

Among the disease-modifying drugs (DMDs) for multiple sclerosis (MS), glatiramer acetate was associated with a lower hazard of hypertension, presenting a potential positive impact on cardiovascular health.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 19, 2024.

Investigators identified practical guidelines for NMOSD management, emphasizing patient communication and targeted therapies, while providing recommendations for personalized approaches.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Ahmed Obeidat, MD, PhD, considers utility of biomarkers in MS diagnosis, but he also noted that diagnosis remains clinical.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss the role of biomarkers and the key areas in which they will be used in managing day-to-day decisions in patient management.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Using a sample of 350 pregnancies, the maintenance of natalizumab during pregnancy past the 30th week had both positive and negative impacts, suggesting a risk-benefit discussion may be needed before patients begin treatment.

Neurology News Network for the week ending January 13, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.

A recent analysis revealed patients with neuromyelitis optica spectrum disorder exhibited significantly lower vitamin D levels, suggesting a potential association with impaired immune tolerance in the disorder.